2223 GMT - Pathology services provider Healius's target of a high-single-digit Ebit margin by FY 2027 looks ambitious to Jefferies. Healius expects to reach this goal through a mix of revenue and cost initiatives. However, analyst David Stanton forecasts Healius achieving a 4.4% margin in FY 2028. "Growth in Ebit margin is not expected to be linear in the timeframe--we believe it is likely to be back-ended," Jefferies says. "We estimate that low-end to high-end targets imply FY 2028 Pathology Ebit margins of 7.0% to 8.6%." (david.winning@wsj.com; @dwinningWSJ)
(END) Dow Jones Newswires
March 27, 2025 18:23 ET (22:23 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。